全文获取类型
收费全文 | 376篇 |
免费 | 11篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 29篇 |
口腔科学 | 3篇 |
临床医学 | 24篇 |
内科学 | 40篇 |
皮肤病学 | 2篇 |
神经病学 | 21篇 |
特种医学 | 6篇 |
外科学 | 80篇 |
综合类 | 2篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 11篇 |
肿瘤学 | 156篇 |
出版年
2022年 | 5篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 7篇 |
2013年 | 8篇 |
2012年 | 26篇 |
2011年 | 21篇 |
2010年 | 20篇 |
2009年 | 17篇 |
2008年 | 20篇 |
2007年 | 29篇 |
2006年 | 21篇 |
2005年 | 21篇 |
2004年 | 17篇 |
2003年 | 24篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 9篇 |
1999年 | 6篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1992年 | 11篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 6篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1972年 | 1篇 |
1938年 | 1篇 |
1934年 | 1篇 |
1881年 | 1篇 |
排序方式: 共有387条查询结果,搜索用时 9 毫秒
1.
The cytotoxic activity profile of an immunotoxin, SWA11-ricin A chain, recognising a cell-surface antigen associated with human small cell lung cancer (SCLC), was examined in detail using a panel of SCLC, non-SCLC and non lung tumour cell lines in tissue culture. SWA11-ricin A chain was potently and selectively active against three SCLC cell lines of both classic and variant morphologies, inhibiting the incorporation of 3H-leucine with an IC50 of 5 x 10(-11) M. At a concentration of 1 x 10(-8) M, the SWA11 immunotoxin could selectively eliminate in excess of 99.9% of clonogenic tumour cells. Intoxication proceeded rapidly following a 4 h lag phase; the initial rate of protein synthesis inhibition occurred with a t50 of 2 h and a t10 of 7 h. The cytotoxic activity of SWA11-ricin A chain was potentiated by 100-fold in the presence of the carboxylic ionophore monensin at 1 x 10(-7) M. Kinetic studies revealed that monensin enhanced the rate of protein synthesis inhibition by two-fold and eliminated the lag phase suggesting a rapid effect on either the rate or route of internalisation. Studies with SWA11 could detect no influence of monensin on the rate of antibody internalisation and a transient delay in the delivery of internalised antibody to lysosomes was observed by immunoelectron microscopy. 相似文献
2.
M. B. Zimmermann-Hösli R. A. Stahel P. Vogt O. Oelz 《Journal of molecular medicine (Berlin, Germany)》1988,66(20):1010-1014
Summary A rate on autopsy of up to 30% systemic fungal infections and difficulties in diagnosing systemic mycosis antemortem have led to the empiric use of amphotericin B in patients with hematological malignancies, prolonged fever, and neutropenia. Routine empiric antifungal treatment was initiated in our institution in 1982. Amphotericin B was given to granulocytopenic patients with hematological malignancies with (a) unremitting fever after 48–72 h of antibiotic treatment, (b) recurrent fever during antibiotic treatment, or (c) with newly detected pulmonary infiltrates, sinusitis, skin and retinal lesions suggestive of a fungal infection. With this approach the rate of systemic fungal infections decreased significantly from 10% (27 of 270 patients; 1973–1981) to 4% (6 of 153 patients; 1982–1986,P<0.02). The reduction of systemic fungal infections was most prominent in patients with acute myelogenous leukemia, where its proportion decreased from 16% (16 of 98 patients; 1973–1981) to 4% (2 of 50 patients; 1982–1986,P<0.023). Our data support the hypothesis that the incidence of systemic fungal infections in patients with hematological malignancies and especially in acute myelogenous leukemia can be reduced significantly by empirical treatment with amphotericin B. 相似文献
3.
Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex
Breymann C von Seefried B Stahel M Geisser P Canclini C 《Journal of perinatal medicine》2007,35(2):115-118
OBJECTIVE: To study the transfer of parenteral iron sucrose into maternal milk in the postpartum period. STUDY DESIGN: Ten healthy lactating mothers with functional iron deficiency 2-3 days after delivery received 100 mg intravenous iron sucrose and were observed together with a control group (n=5) without iron treatment during four days. Milk samples were taken before the treatment and every day afterwards. RESULTS: Mean milk iron levels at baseline were 0.43 and 0.46 mg/kg in the treatment and control group and decreased until the end of observation in both groups by 0.11 mg/kg. No significant difference between the groups was found on any study day as well as in the mean change from baseline over all four days. CONCLUSION: We could not show transfer of iron-sucrose into maternal milk for the given dosage. Since parenteral iron sucrose is widely used in obstetrics, the results provide information about safety of parenteral iron sucrose in the lactation period. The findings are also in agreement with other reports on active biological mammary gland regulation of milk iron concentration. 相似文献
4.
Priska Stahel Changting Xiao Robert A. Hegele Gary F. Lewis 《The Canadian journal of cardiology》2018,34(5):595-604
Despite the effectiveness of low-density lipoprotein (LDL)-lowering strategies for the treatment of diabetic dyslipidemia, significant residual risk of atherosclerotic cardiovascular disease remains. Residual risk might in part be explained by lipid abnormalities that go beyond LDL cholesterol elevation, collectively termed the “atherogenic dyslipidemia complex (ADC),” consisting of hypertriglyceridemia, elevated small dense LDL particles, reduced high-density lipoprotein cholesterol, and high-density lipoprotein particle numbers, increased remnant lipoproteins, and postprandial hyperlipidemia. In this review, we briefly discuss the pathophysiology of the typical dyslipidemia that occurs in insulin-resistant states including obesity, the metabolic syndrome, and type 2 diabetes. Lipid-modifying strategies including lifestyle modification, ezetimibe, statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors in treating ADC are discussed. With the advent of novel therapies involving antisense oligonucleotides and monoclonal antibodies, new targets can be specifically downregulated to potentially promote lipoprotein clearance or suppress production. We review novel approaches currently undergoing clinical testing and we speculate on their suitability for use in treating ADC for the prevention of atherosclerotic cardiovascular disease. In addition, future targets that might be considered for therapeutic development are discussed. 相似文献
5.
Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells 总被引:1,自引:0,他引:1
Himmelmann A Gautschi O Nawrath M Bolliger U Fehr J Stahel RA 《British journal of haematology》2001,114(2):400-405
Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare disorder of unknown aetiology affecting predominantly young to middle-aged women. It is characterized by a polyclonal expansion of B cells, including typical binucleated lymphocytes, and is associated with the presence of the translocation t(14;18), involving the bcl-2 oncogene. The stage of differentiation of the B cells expanded in PPBL is not known. We analysed the immunophenotype of the expanded B-cell subset in five new patients with PPBL and found a large uniform expansion of a recently defined human memory B-cell population, IgD(+)CD27(+) memory B cells. After in vitro stimulation with interleukin 2 (IL-2) and Staphylococcus aureus Cowan strain I, B cells from PPBL patients produced high levels of IgM immunoglobulins, which is a characteristic feature of IgD(+)CD27(+) memory B cells. Using a quantitative real-time polymerase chain reaction method, we found a high frequency of the translocation t(14;18) in the range of 1000-3000 per 106 B cells in PPBL patients. In contrast, a much smaller number of cells with a t(14;18) was found in B cells from healthy individuals. Our finding that PPBL is an accumulation of memory B cells further suggests that chronic antigeneic stimulation plays an important part in the pathogenesis of this disorder. This IgD(+)CD27(+) memory B-cell population might harbour a certain number of 'physiological' t(14;18) translocations that increases as this population expands in PPBL patients and constitutes the majority of peripheral blood lymphocytes. 相似文献
6.
7.
René Hornung Sonja Spichtig Ana Baños Michèle Stahel Roland Zimmermann Martin Wolf 《Lasers in medical science》2011,26(2):205-212
Preterm labor is a common obstetric complication. Clinical evaluation of cervical ripening to predict preterm labor is very
inaccurate. We used frequency-domain near-infrared spectroscopy (FD-NIRS) to non-invasively investigate the changes of the
optical properties (i.e., absorption and scattering of light) in the uterine cervix during regular pregnancies. Optical properties
of uterine cervices were measured in 13 patients at various time points of regular pregnancies. For each gestational trimester,
mean values with 95% confidence intervals were calculated for oxy-, deoxy-, and total hemoglobin concentration (O2Hb, HHb, tHb), tissue oxygen saturation and water content and statistically significant differences between the trimesters
were determined. The wavelength-dependent scattering (scatter power) was calculated by an exponential fit. O2Hb, and tHb and the scatter power showed an increase as a function of the gestational age. Differences between the second
and the third trimester were statistically significant. HHb and the water content showed no significant change over time.
Our results show that FD-NIRS is a promising diagnostic tool for providing information about cervical content of hemoglobin,
water, and extracellular matrix proteins. We propose this technology to assess the cervical ripening and eventually to predict
preterm labor. 相似文献
8.
9.
G D'Addario D Rauch R Stupp M Pless R Stahel N Mach L Jost L Widmer C Tapia M Bihl M Mayer K Ribi S Lerch L Bubendorf D C Betticher 《Annals of oncology》2008,19(4):739-745
BACKGROUND: Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression. PATIENTS AND METHODS: In all, 63 patients with chemotherapy-naive stage IIIB/IV NSCLC received gefitinib 250 mg/day. At disease progression, gefitinib was replaced by cisplatin 80 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1, 8 for up to six 3-week cycles. Primary end point was the disease stabilization rate (DSR) after 12 weeks of gefitinib. RESULTS: After 12 weeks of gefitinib, the DSR was 24% and the response rate (RR) was 8%. Median time to progression (TtP) was 2.5 months and median overall survival (OS) 11.5 months. Never smokers (n = 9) had a DSR of 56% and a median OS of 20.2 months; patients with epidermal growth factor receptor (EGFR) mutation (n = 4) had a DSR of 75% and the median OS was not reached after the follow-up of 21.6 months. In all, 41 patients received chemotherapy with an overall RR of 34%, DSR of 71% and median TtP of 6.7 months. CONCLUSIONS: First-line gefitinib monotherapy led to a DSR of 24% at 12 weeks in an unselected patients population. Never smokers and patients with EGFR mutations tend to have a better outcome; hence, further trials in selected patients are warranted. 相似文献
10.
Larisa L Belyanskaya Thomas M Marti Sally Hopkins-Donaldson Stefanie Kurtz Emanuela Felley-Bosco Rolf A Stahel 《Molecular cancer》2007,6(1):66